Literature DB >> 35562626

Misdiagnosis in mucopolysaccharidoses.

Karolina Wiśniewska1, Jakub Wolski2, Lidia Gaffke1, Zuzanna Cyske1, Karolina Pierzynowska1, Grzegorz Węgrzyn3.   

Abstract

Mucopolysaccharidosis (MPS) is a group of 13 hereditary metabolic diseases identified in humans (or 14 diseases if considering one MPS type described to date only in mice) in which an enzymatic defect results in the accumulation of glycosaminoglycans (GAG) in the lysosomes of cells. First of all, as a result of GAG storage, the proper functioning of the lysosome is disturbed; then, the cells, and finally, tissue, organs, and the whole organism malfunctions are observed. Due to the rarity, heterogeneity, and multi-systemic and progressive nature of MPS, they present a major diagnostic challenge. Due to the wide variation in symptoms and their similarity to other diseases, MPS is often misdiagnosed, usually as neurological diseases (like autism spectrum disorders, psychomotor hyperactivity, and intellectual disability) or rheumatology and orthopedic disorders (like juvenile idiopathic arthritis, Perthes disease, rickets, and muscular dystrophy). In this review article, we present the problems associated with the possibility of misdiagnosing MPS, discuss what diseases they can be confused with, and suggest ways to reduce these problems in the future.
© 2022. The Author(s), under exclusive licence to Institute of Plant Genetics Polish Academy of Sciences.

Entities:  

Keywords:  Diagnostic procedures; Misdiagnosis; Mucopolysaccharidosis

Mesh:

Substances:

Year:  2022        PMID: 35562626     DOI: 10.1007/s13353-022-00703-1

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   2.653


  65 in total

1.  Cumulative incidence rates of the mucopolysaccharidoses in Germany.

Authors:  F Baehner; C Schmiedeskamp; F Krummenauer; E Miebach; M Bajbouj; C Whybra; A Kohlschütter; C Kampmann; M Beck
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  The clinical and genetic Spectrum of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia.

Authors:  Nouriya Abbas Al-Sannaa; Hind Yousif Al-Abdulwahed; Sami Ibrahim Al-Majed; Issam Hassan Bouholaigah
Journal:  J Community Genet       Date:  2017-09-15

3.  Identifying the need for a multidisciplinary approach for early recognition of mucopolysaccharidosis VI (MPS VI).

Authors:  Yew Sing Choy; Kaustuv Bhattacharya; Shanti Balasubramaniam; Michael Fietz; Antony Fu; Anita Inwood; Dong-Kyu Jin; Ok-Hwa Kim; Motomichi Kosuga; Young Hee Kwun; Hsiang-Yu Lin; Shuan-Pei Lin; Nancy J Mendelsohn; Torayuki Okuyama; Hasri Samion; Adeline Tan; Akemi Tanaka; Verasak Thamkunanon; Meow-Keong Thong; Teck-Hock Toh; Albert D Yang; Jim McGill
Journal:  Mol Genet Metab       Date:  2015-03-26       Impact factor: 4.797

4.  Mucopolysaccharidosis type I disguised as rickets.

Authors:  Partha Pratim Chakraborty; Sugata Narayan Biswas; Sayantan Ray; Santosh Kumar Dey
Journal:  BMJ Case Rep       Date:  2016-05-11

5.  Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses.

Authors:  Joanna Brokowska; Karolina Pierzynowska; Lidia Gaffke; Estera Rintz; Grzegorz Węgrzyn
Journal:  Cell Biol Int       Date:  2020-03-12       Impact factor: 3.612

6.  Cases of inborn errors of metabolism diagnosed in children with autism.

Authors:  Nafiye Emel Cakar; Pınar Yilmazbas
Journal:  Ideggyogy Sz       Date:  2021-01-30       Impact factor: 0.427

7.  MPS screening methods, the Berry spot and acid turbidity tests, cause a high incidence of false-negative results in sanfilippo and morquio syndromes.

Authors:  Chang Chih-Kuang; Lin Shuan-Pei; Lee Shyue-Jye; Wang Tuen-Jen
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

8.  Inborn error metabolic screening in individuals with nonsyndromic autism spectrum disorders.

Authors:  Jaume Campistol; María Díez-Juan; Laura Callejón; Aroa Fernandez-De Miguel; Mercedes Casado; Angels Garcia Cazorla; Reymundo Lozano; Rafael Artuch
Journal:  Dev Med Child Neurol       Date:  2016-03-31       Impact factor: 5.449

9.  Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-05-29       Impact factor: 4.123

Review 10.  Epidemiology of Mucopolysaccharidoses Update.

Authors:  Betul Çelik; Saori C Tomatsu; Shunji Tomatsu; Shaukat A Khan
Journal:  Diagnostics (Basel)       Date:  2021-02-10
View more
  1 in total

Review 1.  Sanfilippo Syndrome: Optimizing Care with a Multidisciplinary Approach.

Authors:  Zuzanna Cyske; Paulina Anikiej-Wiczenbach; Karolina Wisniewska; Lidia Gaffke; Karolina Pierzynowska; Arkadiusz Mański; Grzegorz Wegrzyn
Journal:  J Multidiscip Healthc       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.